Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Deficiency of T cell CD40L has minor beneficial effects on obesity-induced metabolic dysfunction

Reiche ME., den Toom M., Willemsen L., van Os B., Gijbels MJJ., Gerdes N.

Animal Study on Type 2 Diabetes, published in BMJ Open Diabetes Res Care (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
BMJ Open Diabetes Res Care (2019)
Reported sample size
—
Source database
Europe PMC
PMID
31908798
PMCID
PMC6936585
DOI
10.1136/bmjdrc-2019-000829
Citations
11

Abstract (original English)

Objective Obesity-associated metabolic dysfunction increases the risk of multiple diseases such as type 2 diabetes and cardiovascular disease. The importance of the co-stimulatory CD40-CD40L dyad in diet-induced obesity (DIO), with opposing phenotypes arising when either the receptor (aggravating) or the ligand (protective) is deleted, has been described previously. The functions of CD40 and CD40L are cell type dependent. As co-stimulation via T cell-mediated CD40L is essential for driving inflammation, we here investigate the role of T cell CD40L in DIO. Research design and methods CD4CreCD40L fl/fl mice on a C57BL/6 background were generated and subjected to DIO by administration of 15 weeks of high fat diet (HFD). Results HFD-fed CD4CreCD40L fl/fl mice had similar weight gain, adipocyte sizes, plasma cholesterol and triglyceride levels as their wild-type (WT) counterparts. Insulin and glucose tolerance were comparable, although CD4CreCD40L fl/fl mice did have a decreased plasma insulin concentration, suggesting a minor improvement of insulin resistance. Furthermore, although the degree of hepatosteatosis was similar in both genotypes, the gene expression of fatty acid synthase 1 and ATP-citrate lyase had decreased, whereas expression of peroxisome proliferator-activated receptor-α had increased in livers of CD4CreCD40L fl/fl mice, suggesting decreased hepatic lipid uptake in

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueT-LymphocytesAnimalsMice, Inbred C57BLMice, KnockoutMiceMetabolic DiseasesInsulin ResistanceObesityInflammation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research